GLP-1 Medications: How They Work in Weight Management

In recent years, GLP-1 (Glucagon-Like Peptide-1) receptor agonists have gained attention as a novel approach to weight management, particularly among individuals struggling with obesity and type 2 diabetes. Originally developed as treatments for diabetes, these medications are now being prescribed for weight loss due to their unique effects on appetite regulation and glucose metabolism. 

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are a class of medications that mimic the action of the naturally occurring hormone GLP-1. This hormone plays a crucial role in glucose metabolism and appetite regulation. When you eat, GLP-1 is released from the gut, signaling the pancreas to release insulin, which helps lower blood sugar levels. Additionally, GLP-1 slows down gastric emptying and reduces appetite, leading to a feeling of fullness after meals.

Common GLP-1 receptor agonists include:

• Semaglutide (brand names Wegovy, Ozempic)
• Liraglutide (brand name Saxenda)
• Dulaglutide (brand name Trulicity)
• Exenatide (brand names Byetta, Bydureon)
• Tirzepatide (brand name Mounjro) a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.

These medications have been primarily used to manage type 2 diabetes, but some, like Mounjaro,Wegovy, and Saxenda, have been approved specifically for weight loss in individuals with obesity.

How Tirzepatide Differs from Other GLP-1 Medications

Tirzepatide is a newer medication that stands out by targeting both the GLP-1 and GIP receptors. This dual action not only enhances the effects seen with traditional GLP-1 agonists but also provides additional benefits in terms of weight loss and glucose control. Clinical studies have shown that Tirzepatide can result in greater weight loss compared to other GLP-1 receptor agonists, making it a promising option for individuals with obesity or those who have struggled to achieve significant weight loss with other treatments.

How Do GLP-1 Medications Aid in Weight Loss?

GLP-1 receptor agonists aid in weight loss through several mechanisms:

1. Appetite Suppression: GLP-1 receptor agonists influence the hypothalamus, the part of the brain that regulates hunger. By increasing the levels of GLP-1 in the body, these medications help reduce appetite, leading to lower caloric intake.
2. Slowing Gastric Emptying: These medications delay the emptying of the stomach, which prolongs the sensation of fullness after eating. This effect not only reduces hunger but also helps to prevent overeating.
3. Improving Insulin Sensitivity: GLP-1 receptor agonists enhance insulin sensitivity, allowing the body to use glucose more effectively. This is particularly beneficial for individuals with type 2 diabetes, as it helps maintain better control of blood sugar levels, which is often associated with easier weight management.
4. Reduction in Glucagon Secretion: Glucagon is a hormone that increases blood sugar levels. GLP-1 medications suppress glucagon secretion, thereby reducing the amount of glucose released by the liver.

The Role of GLP-1 Medications in Treating Obesity

For individuals with obesity, GLP-1 receptor agonists like Mounjaro (tirzepatide) have been shown to be highly effective in promoting weight loss. Clinical trials have demonstrated that individuals taking these medications can lose up to 15-20% of their body weight over a period of one year when combined with lifestyle interventions such as diet and exercise.(9)

However, it's important to note that GLP-1 receptor agonists are most effective when used as part of a comprehensive weight management plan. This plan should include dietary changes, increased physical activity, and behavioral therapy. Relying solely on medication without making lifestyle modifications may result in less substantial weight loss and a higher likelihood of weight regain after discontinuation of the medication .

Potential Side Effects and Considerations

While GLP-1 medications are generally well-tolerated, they are not without side effects. Common side effects include:

• Nausea and Vomiting: These are the most commonly reported side effects, especially during the initial weeks of treatment.
• Diarrhea or Constipation: Gastrointestinal issues are also frequently reported.
• Headache and Dizziness: Some individuals may experience mild headaches or dizziness.

Less common but more serious side effects can include:

• Pancreatitis: Inflammation of the pancreas is a rare but serious side effect.
• Gallbladder Disease: There is a slightly increased risk of gallbladder disease, most commonly, gallstones.
• Thyroid Tumors: Some animal studies have suggested a potential risk of thyroid C-cell tumors, though this has not been confirmed in humans .

Who Should and Shouldn’t Use GLP-1 Medications?

GLP-1 receptor agonists are generally prescribed for individuals who:

• Have a BMI of 30 or higher (obesity).
• Have a BMI of 27 or higher with at least one weight-related condition, such as type 2 diabetes or High blood pressure.
• Are unable to achieve adequate weight loss through diet and exercise alone.

However, these medications are not suitable for everyone. They are not recommended for individuals with a personal or family history of pancreatitis, certain thyroid cancers, or multiple endocrine neoplasia syndrome type 2 (MEN 2). Pregnant or breastfeeding women should also avoid these medications .

The Importance of Lifestyle Changes

While GLP-1 receptor agonists can be a powerful tool in weight management, they are most effective when combined with lifestyle changes. Diet, exercise, and behavioral modifications are critical components of any weight loss plan. GLP-1 medications can help reduce appetite and improve metabolic health, but sustainable weight loss requires long-term changes in diet and physical activity .

Conclusion

GLP-1 receptor agonists represent a promising option for individuals struggling with obesity, particularly when other methods have failed. By suppressing appetite, slowing gastric emptying, and improving insulin sensitivity, these medications can significantly aid in weight loss. However, they are not a standalone solution. For the best results, GLP-1 medications should be used in conjunction with a comprehensive lifestyle plan that includes healthy eating, regular exercise, and behavioral therapy.

At Valeo, we are committed to helping you achieve your health and wellness goals safely and effectively. Our platform offers a range of health solutions, including at-home blood testing, personalized health coaching, and supplements to support your weight loss journey. Remember, sustainable weight loss is a marathon, not a sprint. By making informed decisions and taking a holistic approach to your health, you can achieve lasting results.

References

1. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & LEADER Steering Committee. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
2. Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., ... & Wilding, J. P. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA, 314(7), 687-699.
3. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., ... & Rubino, D. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413.
4. Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., ... & Umpierrez, G. E. (2019). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary. Endocrine Practice, 25(1), 69-100.
5. Davies, M. J., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K., Jabbour, S., Rosenstock, J., & NN9535-4370 Investigators. (2017). Effect of liraglutide on cardiovascular outcomes in patients with type 2 diabetes. The Lancet, 389(10073), 1817-1824.
6. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
7. Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., ... & Rubino, D. (2020). Semaglutide 2.4 mg for the treatment of obesity in adults: a systematic review and meta‐analysis. Obesity, 28(6), 1050-1061.
8. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wadden, T. (2015). A randomized, controlled trial of 3.0
9. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080?guestAccessKey=1d98a3bc-0a11-444c-a21a-2b875588f3f0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070824